Q-omics provides the consensus-scored ZNF385D profile across patient tissues and cancer cell-line models. ZNF385D expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF385D is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, ZNF385D RNA expression shows 18,651 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KICH, and LSCC as cancer lineages where ZNF385D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF385D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF385D survival associations across molecular data types. ZNF385D RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF385D RNA expression–survival associations across cancer types. High ZNF385D expression shows unfavorable associations in UVM, MESO, BLCA, KICH and LUSC, but favorable associations in ACC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF385D RNA expression.
This table summarizes ZNF385D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF385D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF385D shows lower tumor expression in KICH, BLCA, KIRP, KIRC, COAD and THCA. The KICH box plot shows higher ZNF385D RNA expression in normal versus tumor tissue (log2 FC = −1.707, t-test p < 0.001).
This table shows molecular features associated with ZNF385D in patient tissues and cancer cell lines. In patient samples, ZNF385D shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF385D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
